Key Takeaway:
- The Hims & Hers peptide market gained attention as shares rose 6% after HHS advanced a proposal on compounded peptides for White House review.
- Regulatory changes could open growth opportunities for Hims & Hers in the peptide market, depending on which substances qualify.
- Safety concerns remain: The proposal does not mean the peptides have received FDA approval, and evidence on their safety and effectiveness is limited.
Hims & Hers Health shares rose 6% Thursday as a proposal to ease restrictions on compounded peptides advanced, creating a potential growth opportunity in the Hims & Hers peptide market.Copy replacement
HHS moves proposal toward white house review
The Department of Health and Human Services submitted an interim access policy for compounding certain peptides to the White House Office of Management and Budget on Tuesday, according to a government filing reported Thursday. The proposal could allow specialty pharmacies to prepare selected peptides under a policy that gives regulators discretion over enforcement.
The filing does not specify which substances would qualify or explain the policy’s full terms. The Associated Press, citing two people familiar with the plan, reported that it is intended to cover popular substances such as BPC-157, which wellness influencers promote for injury recovery and muscle growth.
The proposal follows a July meeting in which an advisory committee recommended easing restrictions on six of seven peptides under review by the Food and Drug Administration. The recommendations differed from FDA staff scientists’ conclusions that available evidence was insufficient to establish the substances’ safety and effectiveness.
The latest move could provide a regulatory opening for companies seeking to sell peptide-based wellness products. However, the proposal remains under review, and broader access would not mean the substances had received FDA approval.
Hims & hers peptide market: growth prospects
Hims & Hers, which provides health care services and prescriptions through its digital platform, has been preparing to expand into peptide products as consumer interest in wellness and longevity treatments grows.
Chief Executive Andrew Dudum said during the company’s second-quarter earnings call that it was developing a peptide offering involving U.S.-manufactured products, clinical guidance and ongoing blood testing. The company has also been preparing its supply chain while awaiting regulatory decisions.
Hims & Hers has previously said it plans to introduce certain peptides that are already permitted for compounding before the end of 2026. Its longer-term plans include substances whose availability depends on regulatory decisions.
Health Secretary Robert F. Kennedy Jr. has publicly supported broader peptide access. In February, he said on The Joe Rogan Experience podcast that he was a “big fan” of peptides and had used them himself with positive results for injuries.
Investors have viewed a potential expansion as a growth opportunity for Hims & Hers. Wall Street analysts have estimated the peptide market could be worth $2 billion to $3 billion, although the size of the market does not guarantee future revenue for the company.
Safety Concerns Remain as Regulators Weigh Changes
Peptides are short chains of amino acids, the building blocks of proteins. Some peptide-based medicines have established medical uses, but many injectable products promoted for anti-aging, muscle recovery, energy, and other wellness goals have not undergone the clinical testing required to establish their safety and effectiveness.
The FDA previously restricted the compounding of BPC-157 and other peptides over safety concerns. Potential risks include contamination, allergic reactions, and tumor growth, according to the agency.
Compounding pharmacies prepare customized medications for individual patients under specific legal conditions. A policy allowing greater access to selected substances would not be equivalent to full FDA approval, which requires evidence supporting a drug’s safety and effectiveness for its intended use.
The White House review is an important step, but the administration has not disclosed the final policy or confirmed when it might take effect. HHS and the FDA did not immediately respond to requests for comment reported Thursday.
Growth in the Hims & Hers peptide market depends on regulatory decisions, product availability, and consumer demand. For patients, experts’ central concern remains whether the products can be supplied under appropriate safeguards and supported by reliable evidence.
